321 related articles for article (PubMed ID: 22612236)
1. Early-mid term follow-up results of percutaneous closure of the interatrial septal defects with occlutech figulla devices: a single center experience.
Aytemir K; Oto A; Ozkutlu S; Kaya EB; Canpolat U; Yorgun H; Sahiner L; Kabakçi G
J Interv Cardiol; 2012 Aug; 25(4):375-81. PubMed ID: 22612236
[TBL] [Abstract][Full Text] [Related]
2. Percutaneous atrial shunt closure using the novel Occlutech Figulla device: 6-month efficacy and safety.
Van Den Branden BJ; Post MC; Plokker HW; Ten Berg JM; Suttorp MJ
J Interv Cardiol; 2011 Jun; 24(3):264-70. PubMed ID: 21198853
[TBL] [Abstract][Full Text] [Related]
3. The Occlutech Figulla PFO and ASD occluder: a new nitinol wire mesh device for closure of atrial septal defects.
Krizanic F; Sievert H; Pfeiffer D; Konorza T; Ferrari M; Hijazi Z; Jung C; Lauten A; Figulla HR
J Invasive Cardiol; 2010 Apr; 22(4):182-7. PubMed ID: 20351390
[TBL] [Abstract][Full Text] [Related]
4. Transcatheter interatrial septal defect closure in a large cohort: midterm follow-up results.
Aytemir K; Oto A; Özkutlu S; Canpolat U; Kaya EB; Yorgun H; Şahiner L; Sunman H; Ateş AH; Kabakçı G
Congenit Heart Dis; 2013; 8(5):418-27. PubMed ID: 23601507
[TBL] [Abstract][Full Text] [Related]
5. [Percutaneous closure of interatrial septal defects: mid-term follow-up results].
Oto MA; Aytemir K; Ozkutlu S; Kaya EB; Kabakcı G; Ateş AH; Yorgun H; Canpolat U
Turk Kardiyol Dern Ars; 2011 Jul; 39(5):385-95. PubMed ID: 21743262
[TBL] [Abstract][Full Text] [Related]
6. Electrocardiographic changes and arrhythmias following percutaneous atrial septal defect and patent foramen ovale device closure.
Johnson JN; Marquardt ML; Ackerman MJ; Asirvatham SJ; Reeder GS; Cabalka AK; Cetta F; Hagler DJ
Catheter Cardiovasc Interv; 2011 Aug; 78(2):254-61. PubMed ID: 21563292
[TBL] [Abstract][Full Text] [Related]
7. The Flatstent versus the conventional umbrella devices in the percutaneous closure of patent foramen ovale.
Aral M; Mullen M
Catheter Cardiovasc Interv; 2015 May; 85(6):1058-65. PubMed ID: 25413379
[TBL] [Abstract][Full Text] [Related]
8. Mid-term results of interventional closure of patent foramen ovale with the Occlutech Figulla
Neuser J; Akin M; Bavendiek U; Kempf T; Bauersachs J; Widder JD
BMC Cardiovasc Disord; 2016 Nov; 16(1):217. PubMed ID: 27832757
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous closure of patent foramen ovale and atrial septal defect: procedure outcome and medium-term follow-up.
Egred M; Andron M; Albouaini K; Alahmar A; Grainger R; Morrison WL
J Interv Cardiol; 2007 Oct; 20(5):395-401. PubMed ID: 17880337
[TBL] [Abstract][Full Text] [Related]
10. The efficiency and safety of percutaneous closure of secundum atrial septal defects with the Occlutech Figulla device: initial clinical experience.
Ilkay E; Kaçmaz F; Ozeke O; Turan RS; Firat S; Pampal K; Ozer E; Bilgin S
Turk Kardiyol Dern Ars; 2010 Apr; 38(3):189-93. PubMed ID: 20675996
[TBL] [Abstract][Full Text] [Related]
11. Transcatheter closure of atrial septal defect with the Figulla(®) ASD Occluder: a comparative study with the Amplatzer(®) Septal Occluder.
Godart F; Houeijeh A; Recher M; Francart C; Polge AS; Richardson M; Cajot MA; Duhamel A
Arch Cardiovasc Dis; 2015 Jan; 108(1):57-63. PubMed ID: 25453168
[TBL] [Abstract][Full Text] [Related]
12. Transcatheter closure of secundum ASD using Occlutech Figulla-N device in symptomatic children younger than 2 years of age.
Ammar RI; Hegazy RA
J Invasive Cardiol; 2013 Feb; 25(2):76-9. PubMed ID: 23388225
[TBL] [Abstract][Full Text] [Related]
13. Percutaneous closure of atrial septal defects: a decade of experience at a reference center.
Fiarresga A; De Sousa L; Martins JD; Ramos R; Paramés F; Freitas I; Oliveira JA; Trigo C; Agapito A; Ferreira RC; Pinto F
Rev Port Cardiol; 2010 May; 29(5):767-80. PubMed ID: 20866006
[TBL] [Abstract][Full Text] [Related]
14. Incidence, timing, and predictive factors of new-onset migraine headache attack after transcatheter closure of atrial septal defect or patent foramen ovale.
Rodés-Cabau J; Mineau S; Marrero A; Houde C; Mackey A; Côté JM; Chetaille P; Delisle G; Bertrand OF; Rivest D
Am J Cardiol; 2008 Mar; 101(5):688-92. PubMed ID: 18308022
[TBL] [Abstract][Full Text] [Related]
15. Initial experience with a transcatheter septal closure system for secondary stroke prevention in patients with interatrial septal defects.
Silverman IE; Kiernan FJ; Kelsey AM; Brakoniecki JJ; Kazi FA; Dougherty JE; Boden WE; McKay RG
Conn Med; 2003 Mar; 67(3):135-44. PubMed ID: 12687787
[TBL] [Abstract][Full Text] [Related]
16. Risk of cerebral embolism after interventional closure of symptomatic patent foramen ovale or atrial septal defect: a diffusion-weighted MRI and neuron-specific enolase-based study.
Oktay Tureli H; Ungan I; Tureli D; Demir B; Pirhan O; Bayrak HI; Caglar IM; Karakaya O; Inci E
J Invasive Cardiol; 2013 Oct; 25(10):519-24. PubMed ID: 24088426
[TBL] [Abstract][Full Text] [Related]
17. Taming the "cobra": an approach to "cobra-like" formation seen in the Occlutech atrial septal defect and patent foramen ovale occluders.
Aaron S; Mainzer G; Lorber A
Catheter Cardiovasc Interv; 2012 Mar; 79(4):678-80. PubMed ID: 21805618
[TBL] [Abstract][Full Text] [Related]
18. Percutaneous closure of inter-atrial communications (atrial septal defect and patent foramen ovale): single-centre experience and mid-term follow-up.
Van de Bruaene A; Stroobants D; Benit E
Acta Cardiol; 2015 Apr; 70(2):133-40. PubMed ID: 26148372
[TBL] [Abstract][Full Text] [Related]
19. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies.
Abaci A; Unlu S; Alsancak Y; Kaya U; Sezenoz B
Catheter Cardiovasc Interv; 2013 Dec; 82(7):1123-38. PubMed ID: 23412921
[TBL] [Abstract][Full Text] [Related]
20. Impact of Percutaneous Closure of Interatrial Shunts on Migraine Attacks: Single-Operator Series and Review of the Literature.
Manolis AS
Rev Recent Clin Trials; 2017; 12(2):129-138. PubMed ID: 28356032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
